Back to Khiron or All Oil Concentrates

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This product was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Dosing Look-Up Table (Estimated)

0.01/g1.2/mg THC1.4/mg CBD
0.05/g6/mg THC7/mg CBD
0.1/g12/mg THC14/mg CBD
0.15/g18/mg THC21/mg CBD
0.2/g24/mg THC28/mg CBD
0.25/g30/mg THC35/mg CBD
0.3/g36/mg THC42/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
Flag of Colombia Bogotá, Colombia Khiron
Designation
Khiriox T12:C14
Chemotype
Type II: THC/CBD Mix
Carrier Oil
Medium-Chain Triglycerides
THC Potential Range (±10%)
10.8-13.2/mg
CBD Potential Range (±10%)
12.6-15.4/mg
Cultivated or Packaged in
Flag of North Macedonia North Macedonia
Imported by
United Kingdom Curaleaf Laboratories

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Available

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Main Partner Pharmacy

Pharmacy Distributor

Dispensing Patient Pharmacies

Product DescriptionPatient Reviews

Flag of Colombia Bogotá, Colombia About Khiron Life Sciences Corp

Khiron Logo

Founded in October 2019, working assiduously to provide best care possible to patients in the UK. That is why our primary goal is to facilitate access to high-quality cannabis-based pharmaceutical products.

Khiron Life Sciences UK was founded in October 2019 and has been working assiduously to provide best care possible to patients in the UK. That is why our primary goal is to facilitate access to high-quality cannabis-based pharmaceutical products.

Putting our patients first is what allowed Khiron Life Sciences to become the medical cannabis market leader in Latin America.

Our team is composed of experienced professionals from of the European medical cannabis industry. We are working closely with the London-based leading independent scientific body, Drug Science, responsible for Project Twenty21, the largest medical cannabis patient registry in Europe.

khironmed.co.uk

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)